FibroGen’s pamrevlumab disappointing results marks second failure in a row – Pharmaceutical Technology
FribroGen received $150m in non-dilutive funding from Morgan Stanley Tactical Value for pamrevlumab commercialisation. Image Credit: fran_kie / Shutterstock. FibroGen’s lead candidate pamrevlumab failed to